Trial · NCT07885228
Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
NCT07885228, Phase 1, Phase 2, Not yet recruiting, Nanfang Hospital, Southern Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease. Trials, record NCT07885228. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885228
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
- NCT number
- NCT07885228
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 49 participants, estimated
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Conditions
- Acute Graft vs Host Disease
- Interventions
- Jaktinib
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) | Day 28 | The proportion of patients who had a complete response or partial response as compared with baseline organ staging without the use of additional systemic therapy for acute GVHD. |
| Secondary | Durable overall response (DOR) at Day 56 | Day 56 | The proportion of patients who had response at day 28 that was maintained at day 56. |
| Secondary | Best Overall Response (BOR) | Day 56 | The proportion of patients who achieved a complete response or partial response at any time point up to and including Day 56 and before the start of additional systemic therapy for aGVHD. |
| Secondary | Overall response rate (ORR) | Day 56 | The proportion of patients who had a complete response or partial response as compared with baseline organ staging without the use of additional systemic therapy for acute GVHD. |
| Secondary | Overall Survival (OS) | 1 year | The time from the date of enrollment to the date of death due to any cause. |
| Secondary | Failure-Free Survival (FFS) | 1 year | The time from the date of enrollment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. |
| Secondary | Relapse-Free Survival (RFS) | 1 year | The interval from enrollment to the date of death from any cause in the absence of hematologic disease relapse or progression. |
| Secondary | Disease Relapse Rate | 1 year | Cumulative incidence of hematological malignancy relapse or progression. |
| Secondary | Event-Free Survival (EFS) | 1 year | Time from the date of enrollment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. |
| Secondary | Incidence of Chronic Graft-Versus-Host Disease (cGVHD) | 1 year | Cumulative incidence of cGVHD post-allogeneic hematopoietic stem cell transplantation. cGvHD, defined as the diagnosis of any cGvHD including mild, moderate, severe. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885228
GET https://conductscience.org/api/trials/v1/NCT07885228/registered